세계의 이식용 HLA 타이핑 시장 : 기술별, 제품별, 용도별, 유형별, 최종사용자별 - 예측(-2030년)

The global HLA typing for transplant market is projected to reach USD 1.4 billion by 2030 from USD 1.1 billion in 2025, at a CAGR of 6.0% during the forecast period. The growth of the HLA typing market is being propelled by several key factors: the development of sophisticated HLA typing technologies, a rising demand for organ transplantation, strategic government efforts aimed at improving organ donation rates, and an expansion of research initiatives focused on HLA typing methodologies.

By technology, the molecular assays segment accounted for the largest market share in 2024.

The HLA typing for transplant market, by technology, is segmented into non-molecular and molecular assays. In 2024, the molecular assay technologies segment dominated the HLA typing market for transplants, reflecting a significant trend towards the utilization of molecular approaches among end users. This dominance is driven by a concerted emphasis from manufacturers on advancing high-resolution assays within molecular platforms, enhancing the accuracy and reliability of HLA typing for transplantation purposes.

By end user, the independent reference laboratories segment accounted for the largest market share in 2024

The HLA typing for transplant market is segmented based on end users into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2024, independent reference laboratories are projected to dominate the market, driven by a stronger inclination among diagnostic labs to outsource HLA typing services to biotech firms. This shift is facilitated by the advent of high-resolution molecular techniques and the rising number of strategic partnerships between reference laboratories and transplantation centers, enhancing service efficiency and diagnostic precision.

North America accounted for the largest market share, by region, in 2024.

In 2024, North America dominated the HLA typing market for transplant applications, closely followed by Europe. This trend can be attributed to several factors, including the availability of cutting-edge diagnostic technologies, a robust ecosystem of manufacturers, and a well-established healthcare infrastructure. Furthermore, the region is home to leading biotechnology firms that are active in the R&D of novel HLA alleles. Coupled with rising transplantation rates and supportive reimbursement frameworks, these elements significantly contribute to the market's expansion in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-20%, Tier 2-45%, and Tier 3-35%
• By Designation: C-level-35%, Directors-25%, and Others-40%
• By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America-5%, and the Middle East & Africa-5%

Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Werfen (US), and TBG Biotechnology Corporation (Taiwan).

Research Coverage

This report studies the HLA typing for transplant market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes market opportunities and challenges for stakeholders and details the competitive landscape for market leaders. It is with respect to their growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Rationale to Buy the Report

The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights into the following pointers:

• Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key insights from primary experts
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET ESTIMATION APPROACH
    • 2.2.1.1 Company revenue-based market estimation approach top-down approach
    • 2.2.1.2 Procedure-based market estimation bottom-up approach
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HLA TYPING FOR TRANSPLANT MARKET OVERVIEW
• 4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2024
• 4.3 HLA TYPING FOR TRANSPLANT MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)
• 4.4 HLA TYPING FOR TRANSPLANT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising number of organ donors and transplant procedures
    • 5.2.1.2 Surge in organ failure cases due to increased prevalence of chronic diseases
    • 5.2.1.3 Increasing research activities and rising funding for organ transplantations
    • 5.2.1.4 Growing adoption of HLA typing in personalized medicines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of HLA typing products
    • 5.2.2.2 Shortage of healthy organs for transplants
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Adoption of NGS and automation for high-throughput needs
    • 5.2.3.2 Use of AI and ML in HLA typing for better accuracy and broader clinical utility
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory complexities across regions
    • 5.2.4.2 Lack of standardization across HLA typing laboratories
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY FRAMEWORK
    • 5.3.1.1 North America
      • 5.3.1.1.1 US
      • 5.3.1.1.2 Canada
    • 5.3.1.2 Europe
      • 5.3.1.2.1 UK
      • 5.3.1.2.2 France
      • 5.3.1.2.3 Germany
    • 5.3.1.3 Asia Pacific
      • 5.3.1.3.1 China
      • 5.3.1.3.2 Japan
      • 5.3.1.3.3 India
    • 5.3.1.4 Latin America
      • 5.3.1.4.1 Brazil
      • 5.3.1.4.2 Mexico
    • 5.3.1.5 Middle East & Africa
  • 5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 RESEARCH & DEVELOPMENT
  • 5.4.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.4.3 MARKETING, SALES, AND DISTRIBUTION, AND AFTERMARKET SERVICE
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.5.3 SALES & DISTRIBUTION AGENTS
  • 5.5.4 END USERS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO FOR HS CODE 3822, 2020-2024
  • 5.7.2 EXPORT SCENARIO FOR HS CODE 3822, 2020-2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 LIST OF MAJOR PATENTS/PATENT APPLICATIONS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICING TREND OF INSTRUMENTS, BY TYPE, 2023-2024
  • 5.9.2 AVERAGE SELLING PRICING TREND OF NEXT-GENERATION SEQUENCING INSTRUMENTS, BY KEY PLAYER, 2023-2024
  • 5.9.3 AVERAGE SELLING PRICING TREND OF REAGENTS, BY TYPE, 2022-2024
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Next-generation sequencing
    • 5.10.1.2 PCR-Sequence-specific oligonucleotide probes
  • 5.10.2 COMPLEMENTARY TECHNOLOGIES
    • 5.10.2.1 Single antigen-based assays
    • 5.10.2.2 Flow cytometry crossmatch
  • 5.10.3 ADJACENT TECHNOLOGIES
    • 5.10.3.1 Bioinformatics software
• 5.11 PORTER'S FIVE FORCE ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 THERMO FISHER SCIENTIFIC TO DEVELOP TECHNIQUES FOR ENHANCING HLA TYPING ACCURACY IN TRANSPLANTATION
  • 5.14.2 ILLUMINA TO STREAMLINE HLA TYPING WITH TRUSIGHT HLA SOLUTION
  • 5.14.3 WERFEN TO ACCELERATE HLA TYPING WITH NANOPORE SEQUENCING
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 UNMET NEEDS
• 5.18 IMPACT OF AI/GEN AI ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.18.1 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE-TRANSPLANT EVALUATION
    • 5.18.1.1 AI use cases in HLA typing for transplant market
    • 5.18.1.2 Key companies implementing AI
  • 5.18.2 FUTURE OF AI IN HLA TYPING FOR TRANSPLANT MARKET
• 5.19 IMPACT OF 2025 US TARIFF ON HLA TYPING FOR TRANSPLANT MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 North America
      • 5.19.4.1.1 US
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia Pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES

6 HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & CONSUMABLES
  • 6.2.1 AVAILABILITY OF MULTIPLE VARIETIES OF REAGENTS & CONSUMABLES TO DRIVE ADOPTION IN HLA TYPING PHASES
• 6.3 INSTRUMENTS
  • 6.3.1 NEED FOR PRECISE AND RELIABLE HLA MATCHING IN BONE MARROW AND ORGAN TRANSPLANTS TO PROPEL MARKET GROWTH
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 GROWING AUTOMATION AND DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO AID MARKET GROWTH

7 HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MOLECULAR ASSAYS
  • 7.2.1 PCR-BASED MOLECULAR ASSAYS
    • 7.2.1.1 Sequence-specific primer-PCR
      • 7.2.1.1.1 Cost-effectiveness and high accuracy to drive identification of HLA variants at low to intermediate resolutions
    • 7.2.1.2 Sequence-specific oligonucleotide-PCR
      • 7.2.1.2.1 Development and commercialization of innovative sequence-specific oligonucleotide-PCR products to aid segment growth
    • 7.2.1.3 Real-time PCR
      • 7.2.1.3.1 High sensitivity, effective real-time DNA amplification monitoring, and minimal sample need to drive segment
    • 7.2.1.4 Other PCR-based molecular assays
• 7.3 SEQUENCING-BASED MOLECULAR ASSAYS
  • 7.3.1 SANGER SEQUENCING
    • 7.3.1.1 High accuracy and single-base resolution to detect allelic variants and confirm novel or rare alleles
  • 7.3.2 NEXT-GENERATION SEQUENCING
    • 7.3.2.1 Growing reliance on outsourcing in-house analysis to propel demand in tissue typing
  • 7.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS
• 7.4 NON-MOLECULAR ASSAYS
  • 7.4.1 LOWER COSTS AND HIGHER SPECIFICITY TO DRIVE ADOPTION OVER MOLECULAR ASSAYS

8 HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC APPLICATIONS
  • 8.2.1 ANTIBODY SCREENING
    • 8.2.1.1 Advancement in pre-transplant compatibility screening with NGS to aid segment growth
  • 8.2.2 CHIMERISM MONITORING
    • 8.2.2.1 Growing trend of personalized transplant medicine for effective post-procedural clinical risk management to fuel adoption
  • 8.2.3 OTHER DIAGNOSTIC APPLICATIONS
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS FOR TRANSPLANT DIAGNOSTICS RESEARCH TO FAVOR MARKET GROWTH

9 HLA TYPING FOR TRANSPLANT MARKET, BY TRANSPLANT TYPE

• 9.1 INTRODUCTION
• 9.2 SOLID ORGAN TRANSPLANTS
  • 9.2.1 HIGH POPULARITY OF ORGAN DONATION AND FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET
• 9.3 SOFT-TISSUE TRANSPLANTS
  • 9.3.1 NEED FOR HLA TYPING IN COMPOSITE TISSUE ALLOTRANSPLANTATION TO AID ADOPTION
• 9.4 STEM CELL TRANSPLANTS
  • 9.4.1 EXPANDING DIVERSITY OF DONOR REGISTRIES TO FUEL ADOPTION OF HLA TYPING

10 HLA TYPING FOR TRANSPLANT MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 INDEPENDENT REFERENCE LABORATORIES
  • 10.2.1 ADHERENCE TO QUALITY AND REGULATORY STANDARDS WITH HIGH-QUALITY SERVICES TO DRIVE MARKET GROWTH
• 10.3 HOSPITALS & TRANSPLANT CENTERS
  • 10.3.1 DEVELOPED HEALTHCARE INFRASTRUCTURE AND HIGH SUCCESS RATES IN TRANSPLANT PROCEDURES TO DRIVE MARKET
• 10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 10.4.1 INCREASING COLLABORATIONS TO DEVELOP AND OPTIMIZE HLA TYPING FOR BETTER ACCURACY, SPECIFICITY, AND EFFICIENCY

11 HLA TYPING FOR TRANSPLANT MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to dominate HLA typing for transplant market during forecast period
  • 11.2.3 CANADA
    • 11.2.3.1 Rising number of solid organ and hematopoietic stem cell transplants to drive market adoption of HLA typing
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High donor registration rates and favorable government initiatives to augment market growth
  • 11.3.3 UK
    • 11.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing adoption for donor-recipient compatibility testing to support market
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing popularity of solid organ donation to drive market
  • 11.3.6 ITALY
    • 11.3.6.1 Supportive government policies and strong healthcare infrastructure to spur market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Presence of leading global manufacturers of HLA typing products to drive market
  • 11.4.3 INDIA
    • 11.4.3.1 Rise in transplantation procedures and use of HLA typing for assessing donor-recipient compatibility to spur market growth
  • 11.4.4 JAPAN
    • 11.4.4.1 Increasing number of solid organ transplantation procedures and rising chronic diseases to favor market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing use of genomic testing and analysis and growing government backing for clinical diagnostics to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Government support and advanced healthcare to drive adoption of NGS HLA typing for better transplant outcomes
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Growing elderly demographic and increasing funding from leading HLA typing manufacturers to propel market growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Wide recipient base for organ transplant and rise in medical tourism to fuel market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Improvements in healthcare infrastructure and focus on specialized medical services to augment market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANT MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Technology footprint
    • 12.5.5.5 Application footprint
    • 12.5.5.6 End-user footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 MAJOR PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 ILLUMINA, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services/Solutions offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Expansions
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 QIAGEN
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services/Solutions offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 BIO-RAD LABORATORIES, INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services/Solutions offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services/Solutions offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 CAREDX, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services/Solutions offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 WERFEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services/Solutions offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches
      • 13.1.7.3.2 Deals
  • 13.1.8 DIASORIN S.P.A.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services/Solutions offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product approvals
  • 13.1.9 TBG BIOTECHNOLOGY CORP.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services/Solutions offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 FUJIREBIO
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services/Solutions offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 BECTON, DICKINSON AND COMPANY
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services/Solutions offered
  • 13.1.12 EUROBIO SCIENTIFIC
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services/Solutions offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 PACBIO
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services/Solutions offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product approvals and updates
      • 13.1.13.3.2 Deals
  • 13.1.14 BAG DIAGNOSTICS GMBH
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products/Services/Solutions offered
  • 13.1.15 CREATIVE BIOLABS
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products/Services/Solutions offered
• 13.2 OTHER PLAYERS
  • 13.2.1 HISTOGENETICS LLC
  • 13.2.2 SCISCO GENETICS, INC.
  • 13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
  • 13.2.4 BIONOBIS
  • 13.2.5 TAKARA BIO INC.
  • 13.2.6 KRISHGEN BIOSYSTEMS
  • 13.2.7 SCIENCELL RESEARCH LABORATORIES, INC.
  • 13.2.8 PROIMMUNE LTD.
  • 13.2.9 ALPHA BIOTECH LIMITED
  • 13.2.10 BIOFORTUNA LIMITED

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS